Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans.
We measured antifungal activity against 128 cryptococcal isolates (86 of C. neoformans and 42 of C. gattii) to determine if differences in serotype susceptibility exist. Contrary to previous results, we found no serotype susceptibility differences. Isavuconazole, posaconazole, and voriconazole demonstrated excellent potency against each isolate and serotype, including isolates with reduced fluconazole susceptibilities.
Thompson
George R
GR
Department of Internal Medicine, Division of Infectious Diseases,University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA. thompsong2@uthscsa.edu
Wiederhold
Nathan P
NP
Fothergill
Annette W
AW
Vallor
Ana C
AC
Wickes
Brian L
BL
Patterson
Thomas F
TF
D000935:Antifungal Agents / Q000494:pharmacology*; D003454:Cryptococcus / Q000145:classification / Q000187:drug effects*; D003455:Cryptococcus neoformans / Q000145:classification / Q000187:drug effects*; D015725:Fluconazole / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D009570:Nitriles / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D012703:Serotyping; D014230:Triazoles / Q000494:pharmacology; D065819:Voriconazole
D000935:Antifungal Agents; D009570:Nitriles; D011725:Pyridines; D011743:Pyrimidines; D014230:Triazoles; C508735:isavuconazole; C101425:posaconazole; D015725:Fluconazole; D065819:Voriconazole